Get the weekly note

Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

DYNF vs IBB: how they differ

DYNF and IBB hold 1% of their weight in the same names, and IBB returned more over the year.

iShares U.S. Equity Factor Rotation Active ETF and iShares Biotechnology ETF.

What they hold in common

By the books each fund has filed, DYNF and IBB hold 1% of their money in the same securities at the same weight.

Positions DYNF and IBB both hold, largest shared weight first
HoldingDYNFIBB
GILEAD SCIENCES0.45%7.44%
REGENERON PHARMACEUTICALS0.19%5.92%
UNITED THERAPEUTICS0.09%1.53%
NEUROCRINE BIOSCIENCES0.07%1.14%
BLK CSH FND TREASURY SL AGENCY0.06%0.12%
INSMED0.05%2.02%
USD CASH0.13%0.05%
VERTEX PHARMACEUTICALS0.05%7.94%
AMGEN INC0.04%7.85%
HALOZYME THERAPEUTICS0.04%0.93%
IONIS PHARMACEUTICALS0.04%0.67%
REVOLUTION MEDICINES0.04%2.87%
Largest positions each one holds and the other does not
Only in DYNFOnly in IBB
NVIDIA 8.13%ARGENX SE ADR 3.78%
APPLE 7.62%MODERNA 3.67%
MICROSOFT 4.75%NATERA 3.30%
AMAZON.COM INC 4.09%BEONE MEDICINES AG 2.01%
JPMORGAN CHASE & CO 3.46%ROIVANT SCIENCES LTD 1.56%
EXXONMOBIL HOLDINGS CORP 2.73%GENMAB SPONSORED ADR 1.25%
BROADCOM INC 2.59%ASCENDIS PHARMA 1.20%
META PLATFORMS CLASS A 2.42%MEDPACE HOLDINGS 0.99%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.

DYNF and IBB on the fields both publish, as of Sep 13, 2026. Source: ETFIQ.
DYNF
iShares U.S. Equity Factor Rotation Active ETF
IBB
iShares Biotechnology ETF
Where it sitsCore index fundCore index fund
IssueriSharesiShares
What it isU.S. Equity Factor Rotation ActiveBiotechnology
Total return, 1 year+20.8%+41.5%
S&P 500 over the same days+17.5%+17.5%
Gap to the S&P 500+3.3 pts+24.0 pts
Expense ratio0.26%0.44%
Already in the S&P 50098.8%35.6%
Holdings234233

DYNF in plain words

DYNF is an index equity fund tracking the U.S. Equity Factor Rotation Active. Over the year to Sep 11, 2026 it returned +20.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.26% a year. By its holdings filed for Sep 10, 2026, 99% of the fund by weight is stocks the S&P 500 also holds, across 234 positions, with the top ten at 40.3%.

IBB in plain words

IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Sep 10, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 233 positions, with the top ten at 47.5%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, DYNF or IBB?
In the year to Sep 13, 2026, with distributions reinvested, DYNF returned +20.8% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
Which is cheaper, DYNF or IBB?
DYNF charges 0.26% a year and IBB charges 0.44%, so DYNF is cheaper. Fees come from each fund's prospectus.
How much do DYNF and IBB overlap with the S&P 500?
By their latest filed holdings, 99% of DYNF and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

DYNF against IBB, ETFIQ, data as of Sep 13, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, DYNF against IBB, data as of Sep 13, 2026. https://etfiq.com/compare/any/dynf-vs-ibb Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources